CARLSBAD, CA, USA I October 7, 2013 I Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that GlaxoSmithKline (GSK) has added a development candidate ISIS-GSK3Rx, to its collaboration with Isis. Isis earned $7 million in milestone payments associated with the advancement of this program. ISIS-GSK3Rx is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3Rx to Phase 2 proof-of-concept, after which GSK has an exclusive option to in-license the program and further develop and commercialize the asset.
“We are pleased with the progress of our collaboration with GSK and look forward to achieving further successes, including advancing ISIS-GSK3Rx into clinical studies. The benefit of GSK’s expertise enables us to further expand the breadth of our pipeline into areas where effective new therapies are needed,” said B. Lynne Parshall, chief operating officer of Isis.
As a part of the alliance, Isis is eligible to earn additional pre-licensing milestone payments from GSK as ISIS-GSK3Rx advances. Isis is also eligible to receive double-digit royalties on sales of ISIS-GSK3Rx. The alliance applies Isis’ antisense drug discovery platform to discover and develop new therapeutics against targets for rare and/or serious diseases.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis’ partner, Genzyme, is commercializing Isis’ lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
SOURCE: Isis Pharmaceuticals
Post Views: 252
CARLSBAD, CA, USA I October 7, 2013 I Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that GlaxoSmithKline (GSK) has added a development candidate ISIS-GSK3Rx, to its collaboration with Isis. Isis earned $7 million in milestone payments associated with the advancement of this program. ISIS-GSK3Rx is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3Rx to Phase 2 proof-of-concept, after which GSK has an exclusive option to in-license the program and further develop and commercialize the asset.
“We are pleased with the progress of our collaboration with GSK and look forward to achieving further successes, including advancing ISIS-GSK3Rx into clinical studies. The benefit of GSK’s expertise enables us to further expand the breadth of our pipeline into areas where effective new therapies are needed,” said B. Lynne Parshall, chief operating officer of Isis.
As a part of the alliance, Isis is eligible to earn additional pre-licensing milestone payments from GSK as ISIS-GSK3Rx advances. Isis is also eligible to receive double-digit royalties on sales of ISIS-GSK3Rx. The alliance applies Isis’ antisense drug discovery platform to discover and develop new therapeutics against targets for rare and/or serious diseases.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis’ partner, Genzyme, is commercializing Isis’ lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
SOURCE: Isis Pharmaceuticals
Post Views: 252
